Patients in North America wait a median of three hours to receive intravenous therapy for acute heart failure, while no other region in the world waited for more than 1.2 hours, according to a global study whose lead author and co-primary investigator is Sean Collins, MD, MSc, professor of Emergency Medicine.

The protein MMP7 is elevated in blood from patients with Duchenne muscular dystrophy who have cardiac dysfunction, suggesting that it may be a biomarker for heart disease severity.

Vanderbilt scientists have discovered that a certain enzyme plays a crucial role in preventing obesity-related cardiac dysfunction.

When buying and selling real estate, how often have you heard the realtor’s mantra — location, location, location? This is also the central theme of a recently released journal report on factors that can predict heart failure risk.

The first large study to report that HIV-infected people have a significantly higher risk of heart failure in the antiretroviral therapy era has been published in JAMA Cardiology.

A new computer algorithm developed at Vanderbilt could save billions of dollars in health care costs by identifying patients at risk for readmission after being hospitalized for heart failure.

Vanderbilt researchers have identified biomarkers that could be useful for evaluating and treating pregnancy-related heart failure.